Maria Carmela Piccirillo

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 497 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +16

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 392 citations

Medicine, Gynecology, Oncology +12

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo et al. · Journal of Clinical Oncology · 2012 · 234 citations · Full text

Medicine, Oncology, Pharmacology +16

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

Uwe Wagner, Christian Marth, R. Largillier et al. · British Journal of Cancer · 2012 · 186 citations · Full text

Medicine, Oncology, Pharmacology +17

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Sandro Pignata, Domenica Lorusso, Giovanni Scambia et al. · The Lancet Oncology · 2015 · 172 citations · Full text

Medicine, Oncology, Pharmacology +13